Sandeep Singh
Managing Director
Notable Quotes
We crossed 3,000 crores. So it's been a fantastic year and I will let Vikas fill in more details.
Medtech can be like Generic Two, you know, Version 2.0, and India can become a supplier globally to the best parts of the world.
In four to five years, both businesses will have an EBITDA margin of 25%.
I think after biotech this could be one very valuable subsidiary that we will create in the long term.
We are very clear about it. We will run it independently and it is different but it falls under healthcare.
We are confident that our ongoing cost optimization efforts will persist in driving improved performance.
We have crossed INR 1,000 crore for the quarter for the first time.
Our growth in chronic therapy segment continues to outperform the market, delivering sales of 15.8% year-on-year, whereas the industry only grew by 9.9%.
Trade generics is also not a great word for this business because these are brands actually. These are trade brands, we could call them.